Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights
Tonix reported Q2 2026 net product revenue of $13.5 million, driven primarily by TONMYA net sales of $11 million, which increased 197% quarter-over-quarter following the product's commercial launch. Commercial execution advanced with payer coverage expanding to approximately 136 million lives (43% of U.S. total) and total prescriptions growing 100% quarter-over-quarter to 12,592.
Key figures
- Revenue
- 13500000
- Net loss q2
- $40.6 million
- Rd expenses q2
- $19.4 million
- Sga expenses q2
- $36.0 million
- Cash equivalents
- $176.2 million
- Covered lives us
- 136 million
- Tonmya net sales q2
- $11.0 million
- Total prescriptions q2
- 12592
- Tonmya sales growth qoq
- 197%
- Prescriptions growth qoq
- 100%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.